rs2078267 — SLC22A11

SLC22A11 rs2078267 — A Renal Urate Transporter Variant That Tips the Balance Toward Hyperuricemia

The kidney handles roughly 70% of daily uric acid elimination, and a network of transporters on the proximal tubule determines how much urate is reabsorbed back into the blood versus excreted into the urine. OAT4 (organic anion transporter 4)¹¹ OAT4 (organic anion transporter 4)
Encoded by SLC22A11, OAT4 sits on the apical (urine-facing) membrane of proximal tubule cells and exchanges urate for dicarboxylates like α-ketoglutarate is one of these gatekeepers — a lower-affinity but physiologically important urate reabsorber that works alongside the dominant transporter URAT1 (SLC22A12). The rs2078267 variant lies in an intron of SLC22A11 and is associated with altered OAT4 expression or function, with the C allele linked to higher serum urate concentrations and increased gout risk. This is the third major renal urate locus in GeneOps alongside ABCG2 Q141K (rs2231142)²² ABCG2 Q141K (rs2231142)
A secretory transporter on the gut and kidney that exports urate; the T allele reduces function by 53% and SLC2A9 Arg265His (rs3733591)³³ SLC2A9 Arg265His (rs3733591)
GLUT9, the dominant basolateral urate reabsorber in the proximal tubule, and each contributes independently to serum uric acid variance.

The Mechanism

OAT4 is a urate/dicarboxylate exchanger⁴⁴ urate/dicarboxylate exchanger
It swaps intracellular dicarboxylates (α-ketoglutarate, succinate) for luminal urate, pulling uric acid from the tubular fluid back into the cell expressed on the apical membrane of proximal tubule epithelial cells. While URAT1 (SLC22A12) handles the majority of urate reabsorption with higher affinity, OAT4 provides a parallel reabsorption pathway and also serves as an exit route for loop and thiazide diuretics into the tubular lumen — exchanging the diuretic molecule for urate in the process. This dual role is clinically significant: when diuretics are present, OAT4 activity increases urate reabsorption as a byproduct of diuretic secretion, explaining why thiazide and loop diuretics are well-known triggers of hyperuricemia and gout flares.

The rs2078267 variant is intronic (NM_018484.4:c.1059-957C>T), meaning it does not change the OAT4 protein sequence directly. Instead, the C allele likely enhances OAT4 expression or regulatory activity, increasing net urate reabsorption. In the landmark Global Urate Genetics Consortium (GUGC) meta-analysis⁵⁵ Global Urate Genetics Consortium (GUGC) meta-analysis
Köttgen et al. analyzed >140,000 individuals of European descent and identified 28 genome-wide significant urate loci, SLC22A11 was one of the ten replicated transporter loci, with the T allele associated with reduced serum urate (β = −0.073, p = 9.4 × 10⁻³⁸). In the ARIC study cohort⁶⁶ ARIC study cohort
McAdams-DeMarco et al. quantified the per-allele effect at 6.8 µmol/L (~0.11 mg/dL) higher serum urate per copy of the C allele.

The Evidence

The association between rs2078267 and serum urate is one of the most robustly replicated findings in urate genetics. The Köttgen 2013 GUGC study⁷⁷ Köttgen 2013 GUGC study
Köttgen A, et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet. 2013;45(2):145-54 established SLC22A11 as a genome-wide significant locus in >140,000 Europeans (p = 9.4 × 10⁻³⁸), with the 28 replicated loci collectively explaining 7.0% of serum urate variance. The C allele raises serum urate by approximately 6.8 µmol/L (0.11 mg/dL) per copy in an additive fashion.

A critical finding came from the ARIC gene-by-diuretic study⁸⁸ ARIC gene-by-diuretic study
McAdams-DeMarco MA, et al. A urate gene-by-diuretic interaction and gout risk. Arthritis Rheumatol. 2015;67(8):2201-9, which demonstrated a significant interaction between rs2078267 and diuretic use (p = 0.010). Individuals homozygous for the C allele who also took thiazide or loop diuretics had substantially elevated gout incidence, consistent with the molecular mechanism: diuretics compete for OAT4 transport, driving increased urate reabsorption as a side effect of diuretic secretion.

Cross-ancestry replication has been robust. An Indian GWAS⁹⁹ Indian GWAS
Giri AK, et al. Genome wide association study of uric acid in Indian population. Sci Rep. 2016;6:21440 confirmed the association at genome-wide significance in 4,834 individuals (p = 3.26 × 10⁻¹¹) with a larger effect size than in Europeans (β = −10.54 µmol/L for the protective allele). A New Zealand multi-ancestry study¹⁰¹⁰ New Zealand multi-ancestry study
Hollis-Moffatt JE, et al. Association analysis of SLC22A11 and SLC22A12 with gout in New Zealand. Arthritis Res Ther. 2014;16:R75 found the C allele conferred gout risk in Polynesians (OR 1.51) but not in local Europeans, suggesting ancestry-specific modifier effects.

The C allele frequency varies dramatically by ancestry — near-fixed in East Asians (~98%) and very common in Africans (~85%), moderate in South Asians (~59%) and Latinos (~76%), and lowest in Europeans (~47%). This means the variant contributes most to population-level urate variance in Europeans, where both genotypes are common enough to drive measurable differences.

Practical Actions

The clinical significance of this variant is most pronounced in two scenarios: baseline gout risk assessment and medication selection for hypertension. If you carry two copies of the C allele (CC genotype), your renal urate clearance is genetically reduced, making you more susceptible to hyperuricemia — especially if you also carry risk alleles in ABCG2 (rs2231142) or SLC2A9 (rs3733591). The gene-by-diuretic interaction is clinically actionable: CC carriers prescribed thiazide or loop diuretics for hypertension should have their uric acid levels monitored, and alternative antihypertensives (ACE inhibitors, ARBs, or calcium channel blockers) may be preferable if urate is already elevated.

Dietary purine restriction and adequate hydration become more important with this genotype. Tart cherry extract (500–1,000 mg daily) has demonstrated urate-lowering effects in clinical trials and may offer a low-risk complement to lifestyle measures. Vitamin C at 500 mg daily has modest uricosuric effects by competing with urate for renal reabsorption, though the magnitude (~0.5 mg/dL reduction) is smaller than pharmacological options.

Interactions

This variant operates in the same renal urate handling pathway as two other GeneOps variants. ABCG2 Q141K (rs2231142) reduces urate secretion from the gut and kidney — when combined with SLC22A11 CC (increased reabsorption), the net effect is a double hit: less urate exported and more reabsorbed, compounding hyperuricemia risk. SLC2A9 Arg265His (rs3733591) affects GLUT9, the dominant basolateral urate reabsorber — carrying risk alleles at both SLC2A9 and SLC22A11 amplifies the reabsorption side of the equation through two independent transporters.

The diuretic interaction documented for rs2078267 is mechanistically distinct from other urate loci. OAT4 physically transports diuretic molecules, creating a direct pharmacogenomic link that does not exist for ABCG2 or SLC2A9. This makes the SLC22A11 genotype particularly relevant when evaluating diuretic prescriptions.